Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review

Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, surveillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk compared w...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of clinical oncology Ročník 36; číslo 21; s. 2145
Hlavní autori: Turcotte, Lucie M, Neglia, Joseph P, Reulen, Raoul C, Ronckers, Cecile M, van Leeuwen, Flora E, Morton, Lindsay M, Hodgson, David C, Yasui, Yutaka, Oeffinger, Kevin C, Henderson, Tara O
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 20.07.2018
Predmet:
Cancer Survivors - statistics & numerical data
Child
Cohort Studies
Humans
Incidence
Neoplasms, Second Primary - diagnosis
Neoplasms, Second Primary - epidemiology
Risk
Risk Factors
ISSN:1527-7755, 1527-7755
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, surveillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk compared with the general population, with a greater than twofold increased solid tumor risk extending beyond age 40 years. There is a dose-dependent increased risk for solid tumors after radiotherapy, with the highest risks for tumors occurring in or near the treatment field (eg, greater than fivefold increased risk for breast, brain, thyroid, skin, bone, and soft tissue malignancies). Alkylating and anthracycline chemotherapies increase the risk for development of several solid malignancies in addition to acute leukemia/myelodysplasia, and these risks may be modified by other patient characteristics, such as age at exposure and, potentially, inherited genetic susceptibility. Strategies for identifying survivors at risk and initiating long-term surveillance have improved and interventions are underway to improve knowledge about late-treatment effects among survivors and caregivers. Better understanding of treatment-related risk factors and genetic susceptibility holds promise for refining surveillance strategies and, ultimately, upfront cancer therapies.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1527-7755
1527-7755
DOI:10.1200/JCO.2017.76.7764